tbuckley/cabot-search huggingface dataset:
IDENTIFYING THE OPTIMAL ECHOCARDIOGRAPHIC VARIABLES TO PREDICT OUTCOME THROUGH CORRELATION MAPPING IN PATIENTS WITH DILATED CARDIOMYOPATHY
Authors: Kegan Moneghetti, Juyong Kim, Genevieve Giraldeau, Yukari Kobayashi, Kalyani Boralkar, Ingela Schnittger, Euan Ashley, Matthew Wheeler, Francois Haddad
Journal: Journal of the American College of Cardiology (2017)
Arsenic Trioxide Sensitizes Glucocorticoid-Resistant T-Cell Acute Lymphoblastic Leukemia to Dexamethasone through Inactivation of AKT and Downregulation of XIAP.
Authors: Beat C. Bornhauser, Laura Bonapace, Felix K. Niggli, Beat W. Schaefer, Jean-Pierre Bourquin
Journal: Blood (2006)
Evaluation of orally administered 1-Pamitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol (PLAG) for the treatment of chemotherapy-induced neutropenia (CIN) in pancreatic cancer patients undergoing gemcitabine-based chemotherapy: A pilot case-control study.
Authors: Myung-Hwan Kim, Tae Jun Song, Dongwook Oh, Seong Joon Park, Jae Wha Kim, Sun Young Yoon, Hye-Kyung Kim, Ki Young Sohn, Yong-Hae Han, Saeho Chong
Journal: Journal of Clinical Oncology (2015)

e20697 Background: CIN may compromise chemotherapy resulted in severe infection, dose reduction or delayed treatment. PLAG is a monoacetyldiglyceride, a natural product found in the antlers of Sika deer. The aim of this study was to evaluate the effectiveness of synthetic PLAG for the prevention/treatment of CIN. Methods: A total of 48 patients with unresectable pancreatic cancer were treated with gemcitabine (1,000mg/m2 via intravenous infusion) on day 1, 8, 15 of each 4-week schedule and daily erlotinib (100mg orally). Sixteen patients received PLAG (500mg) orally twice daily from the start of the chemotherapy to the completion. The remaining 32 patients were selected for the control group matched by age, performance status, chemotherapy cycle, comorbidity and disease extent. Absolute neutrophil count (ANC) was classified according to the common terminology criteria for adverse event version 4.03. Results: 1) Overall, the PLAG group showed significantly lower incidence of neutropenia (ANC < 1,500 cells/mm3, Grade 2-4), as compared to the control group (37.5 % vs. 81.3%, p < 0.05). 2) Further analysis of patients who developed CIN, there was a tendency that the PLAG group was comprised of relatively mild CIN whereas the control group was comprised of those with more severe CIN. 3) No adverse events related to PLAG administration were observed. Conclusions: PLAG reduced incidence of CIN, suggesting that PLAG can be used in the prevention and/or treatment of CIN, particularly in patients undergoing a severely myelosuppressive chemotherapy regimen.
Analysis of Adverse Events of Dasatinib and Nilotinib in Chronic Phase Chronic Myeloid Leukemia Patients Treated Outside Clinical Trials
Authors: Koung Jin Suh, Ji Yun Lee, Dong-Yeop Shin, Youngil Koh, Soo-Mee Bang, Sung-Soo Yoon, Seonyang Park, Inho Kim, Jeong-Ok Lee
Journal: Blood (2016)
Assessment of influence of hepatitis B or C virus (HBV or HCV) infection on occurence of colorectal liver metastasis (CLM)
Authors: S. Takahashi, T. Kinoshita, N. Saito, M. Sugitoh, A. Ochiai
Journal: Journal of Clinical Oncology (2007)

14559 Background: Rare occurrence of CLM was reported in patients (pts) with HBV or HCV infection, or liver cirrhosis (LC). However, it is obscure whether HBV or HCV infection itself influence occurrence of CLM irrespective of liver cirrhosis (LC). The aim of this retrospective study was to evaluate correlation between HBV or HCV infection and occurrence of CLM. Methods: Subjects of this study were colorectal carcinomas treated by curative resection at our institution between Nov ’92 and Dec ’01 and fulfilled the following criteria; TNM Stage I-III, histologically confirmed colorectal adenocarcinoma, having definitive results of preoperative tests for HB surface antigen (HBsAg) and HCV antibody, and no LC. Results: A total of 1040 pts met the recruitment criteria. Eleven and 60 pts were positive for HBsAg and HCV antibody respectively. Both HBsAg and HCV antibody were negative in the remaining 969 pts. Comparing characteristics between the infection group and the non-infection group, stage (I/II/III: 19/31/21, 305/306/358), lymph node metastasis (present/absent: 51/20, 607/362), histological type (well, mod/por, others: 62/9, 895/74) depth of tumor (T1,T2/T3,T4: 21/50, 358/611), and preoperative CEA level (ng/ml: 6.5±7.5, 9.2±24.6) did not differ between two groups significantly by the chi-square test (stage, lymph node metastasis, histological type, and depth of tumor) and Mann-Whitney’s U test (CEA). Hepatic function of the infection group was slightly worse than those of the non-infection group by student t-test; alb (g/dl: 3.8±0.5, 4.0±0.4, p&lt;0.01), t-bil (mg/dl: 0.8±0.4, 0.7±0.3, p&lt;0.01). When correlations between hepatic recurrence-free survival and clinicopathological factors were examined, depth of tumor (T3.T4), lymph node metastasis, and alb &lt; 3.8g/dl were the independent poor prognostic factors by the Cox regression model. HBV or HCV infection did not correlate with hepatic recurrence-free survival, recurrence- free survival, or overall survival. Conclusions: HBV or HCV infection does not influence on occurrence of CLM. No significant financial relationships to disclose.
DDX41 Is a Tumor Suppressor Gene Associated with Inherited and Acquired Mutations
Authors: Chantana Polprasert, Isabell Schulze, Mikkael A. Sekeres, Hideki Makishima, Bartlomiej P Przychodzen, Naoko Hosono, Jarnail Singh, Richard A Padgett, Xiaorong Gu, Eckhard Jankowsky, Michael Clemente, Brittney Dienes, Sudipto Mukherjee, Utz Krug, Hans-Ulrich Klein, Martin Dugas, Wolfgang E Berdel, Kenichi Yoshida, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Satoru Miyano, Seishi Ogawa, Carsten Müller-Tidow, Jaroslaw P. Maciejewski
Journal: Blood (2014)
Hypofractionation for early breast cancer: First results of the UK standardization of breast radiotherapy (START) trials
Authors: J. A. Dewar, J. S. Haviland, R. K. Agrawal, J. M. Bliss, P. Hopwood, B. Magee, J. R. Owen, M. A. Sydenham, K. Venables, J. R. Yarnold
Journal: Journal of Clinical Oncology (2007)

LBA518 Background: The START Trials (ST-A and ST-B) test the hypothesis that breast cancer is as sensitive to fraction (Fr) size as late reacting normal tissues, with an a/β value of about 4Gy. Methods: The phase III randomised START Trials tested hypofractionated post-operative RT in women with completely excised invasive breast cancer (T1–3, N0–1, M0). Centres opted for either ST-A or ST-B. ST-A tested 50Gy in 25Fr (5 wks) vs 41.6Gy vs 39Gy, both in 13Fr (5 wks). ST-B tested 50Gy in 25Fr (5 wks) vs 40Gy in 15Fr (3 wks). Stratification was by centre, surgery and boost. The primary endpoint was local-regional (LR) relapse. Late normal tissue effects (NTE) were assessed by breast photographs, clinical examination and quality of life (QL) questionnaires. Survival analysis methods were used to estimate rates of relapse and NTEs, and hazard ratios (HR) (with 95%CI). Smoothed estimates of absolute differences in relapse rates were obtained from the rates in the 50Gy control arms and the HR. Results: 2236 (ST-A) and 2215 (ST-B) patients were recruited from 35 UK centres during 1999–2002. Median follow-up is 5.1 years (ST-A) and 6.0 years (ST-B). There were 93 LR relapses in ST-A (4.1% at 5 years, 3.2- 5.0%), with absolute differences in LR relapse rates at 5 years compared with 50Gy of 0.2% (−1.3%−2.6%) for 41.6Gy and 0.9% (−0.8%−3.7%) for 39Gy. The a/β estimate for tumour control was 5.0Gy (−2.7–12.7). In ST-B, there were 65 LR relapses (2.8% at 5 years, 2.1–3.5%), with an absolute difference in LR relapse rates at 5 years of −0.6% (−1.7%−0.9%) for 40Gy vs 50Gy. In ST-A the rate of mild/marked change in photographic breast appearance was lower in 39Gy vs 50Gy (HR 0.69, 0.52–0.91), and similarly for 40Gy vs 50Gy in ST-B (HR 0.83, 0.66–1.04). The a/β estimate for change in breast appearance was 3.1Gy (1.6–4.6). Rates of induration, telangiectasia and breast oedema were lower in 39Gy (ST-A) and 40Gy (ST-B) compared with the 50Gy arms. QL results were consistent with the clinical findings. Conclusions: The fractionation sensitivity of breast cancer is comparable to that of late reacting normal tissues, confirming the results of a recent pilot trial. These results support the use of hypofractionated RT schedules for early breast cancer. No significant financial relationships to disclose.
Imatinib In Very Elderly CML Patients: What Can We Achieve?.
Authors: Roberto Latagliata, Dario Ferrero, Francesco Cavazzini, Malgorzata Monika Trawinska, Massimo Breccia, Mario Annunziata, Fabio Stagno, Mario Tiribelli, Gianni Binotto, Elena Crisà, Pellegrino Musto, Antonella Gozzini, Laura Cavalli, Raffaele Porrini, Michele Cedrone, Antonella Russo Rossi, Patrizia Pregno, Mauro Endri, Antonio Spadea, Gianfranco Giglio, Federica Sorà, Sergio Storti, Ada D'Addosio, Giovanna Rege Cambrin, Luigiana Luciano, Elisabetta Abruzzese, Giuliana Alimena
Journal: Blood (2010)
THE IN-VITRO EFFECT OF PROSTACYCLIN ANALOGUES ON SMALL HUMAN PULMONARY ARTERY: COMPARISON WITH PHOSPHODIESTERASE INHIBITORS
Authors: Azar Hussain, Rob Bennett, Zaheer Tahir, Mubarak Chaudhry, Alyn Morice, Loubani Mahmoud
Journal: Journal of the American College of Cardiology (2017)
Relationships among patient-level factors, religious coping, use of complementary and alternative medicine, and psychological outcomes in men with advanced cancer
Authors: K. Rand, L. D. Cripe, P. Monahan, Y. Tong, K. Schmidt, S. Rawl
Journal: Journal of Clinical Oncology (2009)

e20652 Background: Religious coping and complementary and alternative medicine (CAM) are two resources frequently used to manage distress associated with advanced cancer. However, the relationships among these coping strategies and psychological outcomes in men with advanced cancer are not well studied. We hypothesized that patient-level factors (e.g., demographics, personality) would predict religious coping and CAM use, which would then predict psychological outcomes. Methods: 81 men with advanced cancer were recruited from oncology clinics for this cross-sectional study. Patients completed surveys which included demographic questions, personality measures (Adult Hope Scale, Life Orientation Test-Revised), CAM use, religious coping (Brief R-COPE), and psychological outcomes (Hospital Anxiety and Depression Scale, Post-Traumatic Growth Inventory). Hierarchical regression analyses were conducted with anxiety, depression, and post-traumatic growth as the criterion variables. Results: Higher anxiety scores were predicted by more negative RC (β = 0.50, p = .002), hope-pathways (β = 0.37, p = .033), and less hope-agency (β = -0.55, p = .002). Depression was predicted by lower hope-agency (β = -0.48, p = .021) and less education (β = -0.37, p = .044). Greater post-traumatic growth was predicted by greater positive RC (β = 0.54, p = .003). CAM use did not predict any psychological outcomes. Greater positive RC was predicted by less education (β = -0.39, p = .025). More negative RC was predicted by lower optimism (β = -0.43, p = .006). CAM use was predicted by greater hope-pathways (β = 0.42, p = .046). Conclusions: Religious coping, but not CAM use, was associated with psychological outcomes. Positive RC predicted greater growth, whereas negative RC predicted greater anxiety. Psychological outcomes were related to patient-level factors including hope and education. However, the two dimensions of trait hope had opposite effects. Higher hope-agency predicted less anxiety and depression, whereas higher hope-pathways predicted greater anxiety. These relationships merit further investigation. No significant financial relationships to disclose.
Brief Report: Partial‐ and Full‐Thickness Focal Cartilage Defects Contribute Equally to Development of New Cartilage Damage in Knee Osteoarthritis: The Multicenter Osteoarthritis Study
Authors: Ali Guermazi, Daichi Hayashi, Frank W. Roemer, Jingbo Niu, Emily K. Quinn, Michel D. Crema, Michael C. Nevitt, James Torner, Cora E. Lewis, David T. Felson
Journal: Arthritis & Rheumatology (2016)

To determine the risk of incident cartilage damage at follow-up in subregions that are undamaged at baseline, by comparing tibiofemoral joint compartments with a baseline focal partial-thickness or full-thickness cartilage defect against compartments without any baseline cartilage damage, in knees with and those without radiographic osteoarthritis (OA).We included participants in the Multicenter Osteoarthritis Study for whom there were semiquantitative magnetic resonance imaging readings at baseline and at 30 months. We estimated the risk of incident cartilage defects developing in tibiofemoral compartments with prevalent partial-thickness and full-thickness cartilage defects in only one subregion within the compartment, using tibiofemoral compartments with no baseline cartilage defects as a referent. Logistic regression with generalized estimating equations was used for all analyses, with adjustments for confounders.A total of 374 compartments (359 knees) were included, and 140 knees (39%) had radiographic OA. Compared to compartments with no baseline cartilage defects, those with partial-thickness (adjusted odds ratio 1.62 [95% confidence interval 1.06-2.47]) and full-thickness (adjusted odds ratio 1.92 [95% confidence interval 1.00-3.66]) cartilage defects in a subregion had a higher risk of incident cartilage defects in other subregions in the same compartment.Prevalent focal cartilage defects, regardless of defect depth, in a single subregion within a tibiofemoral joint compartment increase the risk of developing new cartilage damage in other subregions of the same compartment for middle-aged to elderly persons with or at high risk of knee OA.
Rational for targeted polytherapy in sarcoma: Get the genie out of the bottle.
Authors: Sarah N. Dumont, Dan Yang, Amaury Gerard Dumont, Jean-Yves Blay, Jonathan C. Trent
Journal: Journal of Clinical Oncology (2012)

e13519 Background: While a change of paradigm occurred in the last decade from chemotherapy to targeted therapy for cancer treatment, this work investigates the optimal combination of targeted agents with doxorubicin in sarcoma. Methods: Three sarcoma cell lines were studied RD18 (rhabdomyosarcoma), A204 (undifferentiated sarcoma) and TC 71 (Ewing's sarcoma) and exposed to increasing concentrations of vorinostat (HDAC inhibitor), 17-DMAG (Hsp90 inhibitor), abacavir (anti-telomerase) and sorafenib (tyrosine kinase inhibitor) alone, combined 2 by 2, then with doxorubicin. Viability was assessed by MTS assay. The Chou and Talalay combination index (CI) was used to determine additive (CI=1), synergistic (CI&lt;1) or antagonistic effect (CI&gt;1). Cell cycle analysis, measure of apoptosis by Annexin V and caspase 3/7 activity were studied using flow cytometry analysis and luminescent assay. Results: In monotherapy, the agents showed 30% to 90% decrease in viability but abacavir, which remained less active. Combination therapies with vorinostat, sorafenib and 17-DMAG showed strong synergism. Abacavir was found antagonistic with each drug. Either vorinostat or 17DMAG synergized with doxorubicin, achieving 60% cell killing compared to doxorubicin alone 12% (p=0.007). However, no synergy was observed for sorafenib with doxorubicin. The triple therapy vorinostat, 17DMAG and Doxorubicin did not show synergism but transiently increased the subG1 population at 24H, 70% compared to 30% in monotherapy with an increase in early caspase-independent apoptosis (11% to 36%, p= 0.0008). Conclusions: This work provides evidence of synergism of dual combinations of vorinostat, 17DMAG and sorafenib. In adjunction to doxorubicin, these combinations enhance doxorubicin cytotoxicity at therapeutically relevant concentrations. [Table: see text]
Pleural recurrence after needle biopsy of the lung: An analysis in patients with completely resected stage I non-small cell lung cancer
Authors: H. Matsuguma, R. Nakahara, T. Kitamura, T. Kondo, Y. Kamiyama, K. Mori, Y. Tsuura, S. Honjo, K. Yokoi
Journal: Journal of Clinical Oncology (2004)

7177 Background: Percutaneous needle biopsy (PNB) is widely used to obtain tissue for diagnoses in patients with an indeterminate pulmonary nodule. Although tumor seeding into the needle track has been reported often, pleural recurrence after needle biopsy has not yet been widely investigated in operable patients with early stage non-small cell lung cancer. Methods: Between 1986 and 2000, 339 patients with stage I NSCLC underwent complete resection of the lung. We retrospectively reviewed their medical record and investigated the relationship between the diagnostic methods and the recurrence pattern. Results: Preoperative diagnosis was obtained for 294 patients, 223 were diagnosed by bronchoscopy, and 67 were diagnosed by PNB. Among the patients who were not preoperatively diagnosed, 27 were diagnosed by intraoperative needle biopsy (INB), and 14 were diagnosed by wedge resection of the lung. Almost all of the needle biopsy was carried out using the 18-gauge automated cutting biopsy needle (Monopty) since 1994. Tumors diagnosed by needle biopsy including PNB and INB showed smaller tumor sizes and had fewer vessels invasions than those diagnosed by other methods (P < .05). Seventy-one patients had recurrence; distant metastasis occurred in 52 patients, and local recurrence in 22. Among the 22 patients, 8 had pleural recurrence, and 1 had chest wall implantation. In the 9 patients, 7 were diagnosed by needle biopsy. The rate of pleural recurrence including needle track implantation was 0.8% (2 out of 245) in bronchoscopy cases, and 7.3 % (7 out of 94) in needle biopsy cases (P = .003). Among the 9 patients, all four patients without pleural invasion were diagnosed by needle biopsy. Conclusions: Our research has indicated that pleural recurrence could occur as a result of needle biopsy in the same way as chest wall implantation occurs. Furthermore, pleural recurrence may be occurring more frequently than chest wall implantation. Needle biopsy should be avoided in operable patients with stage I non-small cell lung cancer, if the pulmonary lesions have a high probability of being malignant on diagnostic imagings. No significant financial relationships to disclose.
Addition of Rituximab to Mobilization and Conditioning Overcomes the Predictive Value of Follicular Lymphoma International Prognostic Index (FLIPI) Score in Patients with Relapsed FL Undergoing Autologous Stem Cell Transplantation (AUTO).
Authors: Issa F Khouri, Roland Bassett, Barry Samuels, Farzaneh Maadani, Grace-Julia Okoroji, Robyn Harrell, Martin Korbling, Leandro de Padua Silva, Amin Alousi, Chitra Hosing, Sergio Giralt, Marcos de Lima, Paolo Anderlini, Uday Popat, Rosamar Valverde, Yvonne Hsu, Fredrick Hagemeister, Peter McLaughlin, L. Jeffrey Medeiros
Journal: Blood (2008)
Clinico-Pathological Profile and Outcome of Acute Myeloid Leukemia: An Experience of Al-Amal Hematology/Oncology Center In Qatar
Authors: Mohamed A. Yassin, Firyal A Ibrahim, Hanadi R El-Ayoubi, Ruba Y Taha, Ibrahim A El-Hijji, Riham H Negmeddine, Halima A El-Omri, Hisham M El-Sabah, Aisha A Al-Khinji, Zainab O Fawzi, Aliaa M Amer, Asma S Al-Bin Ali, Sara M Al-Mansour, Mohamed Y El-Khalifa, Kamal R Alabboudi, Munir D Jalis, Rami T Kamzoul
Journal: Blood (2010)
Incidence of second and secondary malignancies in patients with CLL: A single institution experience.
Authors: Samir Dalia, Julio C. Chavez, Gelenis Domingo, Estrella M. Carballido, Paibel I. Aguayo-Hiraldo, Kendra Lynn Sweet, Robert M. Crescentini, Lubosh Sokol, Celeste M. Bello, Jennifer L. Cultrera, Bijal D. Shah, Jeffrey E. Lancet, Rami S. Komrokji, Eduardo M. Sotomayor, Javier Pinilla-Ibarz
Journal: Journal of Clinical Oncology (2012)

6568 Background: Patients with chronic lymphocytic leukemia (CLL) have a higher incidence of second malignancies than the general population with one study showing the risk at 2.2 times the general popualtion. The increased incidence is thought to be due to immunosupression which results in decreased cell surveillance and proliferation of malignant cells. Our study aims to present the rate of second malignancies by cancer type in patients with CLL at our institution. Methods: The Moffitt Cancer Center Total Cancer Care (TCC) database was used to identify patients who had a diagnosis of CLL between January 1993-December 2009. Individual charts were reviewed to confirm the diagnosis of CLL, collect demographic data, and to assess for the presence of a second malignancy under an IRB approved protocol. A second malignancy was defined as another malignancy or transformation of CLL reported in the medical record. Second malignancy data was placed in three categories; skin cancers, solid tumor malignancy, and hematologic malignancy. Results: 546 CLL patients were included in the study. Median age was 62.5 years. 84 (43%) were Stage 0 and 62 (32%) were Stage 1 RAI at diagnosis indicating earlier disease. 266 (49%) patients had a second or secondary malignancy. A total of 304 cancers were identified. 14% of patients had more than one malignancy. Melanoma was identified in 44 (16.5%) patients and non-melanoma skin cancer was identified in 54 (20%). Lung cancer was identified as the most frequent solid tumor malignancy with 36 (13.5%) cases, followed by prostate (35), breast (21), colorectal (15), and bladder (14). 10 patients had a Richter’s transformation of their CLL. 26 patients developed either myelodysplastic syndrome or acute myelogenous leukemia. Conclusions: Second malignancies are frequent in CLL patients. Immunosupression, increased UV light exposure, longer life expectancy in low risk CLL, and tertiary cancer center referral bias are likely reasons for these increased rates. Further research is needed to identify the precise mechanism which cause patients with CLL to have higher rates of second malignancies and to identify if there is an increased risk of a specific type of malignancy in patients with CLL.